WASHINGTON / RankWire.AI / – In a recent analysis conducted at the Dana-Farber Cancer Institute and the 23andMe Research Institute, researchers examined genomic data from over 3.3 million individuals, revealing that a rare inherited genetic mutation raises an individual’s overall risk of developing lung cancer by roughly 25 times, and by about 60 times in non-smokers, as published in the journal Science. The study identified the germline variant, known as EGFR T790M, as one of the most potent inherited risk factors for lung cancer uncovered so far.
This mutation takes place in the epidermal growth factor receptor gene, which influences cell growth and division within lung tissue. While somatic EGFR mutations acquired during a person’s lifetime are established drivers of non-small cell lung cancer, the T790M germline variant is inherited from birth and present in all cells. Data from the National Cancer Institute indicates that the mutation occurs in approximately 1 out of every 15,850 individuals in the United States. Lead author Dr. Jaclyn LoPiccolo pointed out that carrying this variant increases lung cancer risk about 62 times among never-smokers, compared to roughly 11 times in those with a smoking history.
Genealogy analysis revealed that the EGFR T790M mutation is disproportionately prevalent among populations in the Southern Appalachian region of Tennessee and Alabama. Evolutionary geneticists traced the origin of this mutation to British and Irish settlers who arrived in North America during colonial times. The mutation’s frequency increased following a genetic bottleneck approximately 200 years ago. Senior study author Dr. Pasi A. Jänne highlighted that although lung cancer screening currently primarily depends on tobacco exposure, discovering significant genetic risk factors could pave the way for targeted low-dose computed tomography screening for non-smoking carriers.
Dana-Farber’s Study Analyzes Genomes of Over 3.3 Million Individuals
Supported by the National Institutes of Health, the research confirmed that the mutation has a strong specific association with lung cancer, showing no significant correlation with 17 other common cancers evaluated in the dataset. Oncologists emphasized that although tobacco exposure remains the primary cause of lung cancer, the increasing prevalence of non-smoking-related lung cancer poses a growing global health challenge. Pharmaceutical companies like AstraZeneca continue to develop targeted tyrosine kinase inhibitors, such as Tagrisso, to treat EGFR-mutated lung cancers when tumors progress.
Co-senior author Dr. Alexander Gusev observed that the findings underscore how a single inherited point mutation can significantly influence disease risk. Experts recommend that individuals with multiple affected family members, unexplained multifocal lung nodules, or roots in Southern Appalachia seek guidance from genetic counselors. The researchers also clarified that carrying the mutation does not guarantee a lung cancer diagnosis, as environmental factors and secondary genetic changes play critical roles in whether malignancy develops during a person’s lifetime.
EGFR Gene’s Role in Cellular Growth and Division
The research team intends to expand observational efforts through the ongoing INHERIT Study, aiming to investigate additional inherited EGFR variants across diverse racial populations. Long-term monitoring will focus on identifying environmental triggers and secondary genomic alterations that determine why some carriers develop tumors while others remain asymptomatic.
Further details on population genetics, risk assessments, and screening strategies are available via peer-reviewed medical repositories and institutional press releases. Upcoming international oncology conferences will feature presentations of new biomarker data to guide future screening protocols.